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and antigen-speciﬁc cell-mediated attack on hepatic cells. Hor-
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hyperinsulinemia followed by hepatocellular necrosis.
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L. Edwards, I.R. Wanless / Best Practice & Research Clinical Gastroenterology 27 (2013) 471–483472The liver may be injured during the course of many diseases that are systemic or predominantly
involve other organs. In this setting, themechanisms of liver injury can be broadly classiﬁed as vascular,
toxic, immune, and hormonal, as summarized in Fig. 1. Despite the large number and variety of initi-
ating factors, the end results are few, including death of hepatocytes or cholangiocytes leading, in
severe cases, to the stereotyped anatomical and clinical patterns of portal hypertension, with or
without cirrhosis.
The vascular pathway usually culminates in obstruction to blood ﬂow with secondary portal hy-
pertension or parenchymal extinction. The innate immunity pathway may involve diverse agents,
especially derived from gut ﬂora or medications, leading to activation of the innate immune system.
The adaptive immune pathway may involve antibody or cell-mediated mechanisms directed against
hepatic cells. The hormonal pathway is principally involved when overnutrition leads to
hyperinsulinemia.1. vascular disease
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Fig. 1. Diagram showing the four main mechanisms of liver injury. These mechanisms can be initiated by many different factors but
the resulting patterns of liver injury are really only three (heavy boxes). These three patterns are governed by the severity and
distribution of vascular obstruction (Mechanism 1). All four mechanisms may lead to death of hepatocytes, cholangiocytes, or si-
nusoidal endothelial cells. With acute injury frommechanisms 2, 3, or 4 there is minimal vascular obstruction and the clinical effects
are related to the loss of function of hepatic cells. If loss of function is not lethal, the effects of secondary vascular obstruction become
clinically dominant. Chronic portal vein obstruction leads to non-cirrhotic portal hypertension. Chronic vascular outﬂow obstruction
leads to cirrhosis. Vascular disease (Mechanism 1) is usually followed by obstruction, either by thrombosis or inﬂammatory injury. In
shock or in the donor liver, ischaemia often occurs without vascular obstruction. The innate and adaptive immune systems
(Mechanisms 2 and 3) cause a variety of insults leading to death of any type of liver cell. When these injuries cause sinusoidal
obstruction, secondary ischaemia causes chronic liver disease. The most important hormonal effect (Mechanism 4) is hyper-
insulinemia. In concert with elevated free fatty acids (FFA), steatosis and ballooning necrosis occur. Release of toxic lipids from dying
hepatocytes leads to secondary inﬂammation and exacerbation of vascular obstruction.
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dependent event but also a secondary event resulting from activity in one or more of the other three
pathways. Thus vascular obstruction is the late common pathway that converts diverse types of injury
to non-cirrhotic portal hypertension or cirrhosis. Understanding these pathways provides a roadmap in
the search for speciﬁc therapeutic interventions.
Abnormal perfusion (The vascular pathway)
The vascular blood supply is critical to the normal functioning of hepatic cells. Hepatic blood ﬂow
can be increased or decreased. The effect of these changes on the tissues depends on the distribution,
severity, rate of onset, and duration of the change. In shock, decreased ﬂow involves thewhole liver and
is usually acute and severe. In congestive heart failure, decreased ﬂow involves the whole liver but is
usually less severe and intermittent over a period of months or years. Many diseases cause local
intrahepatic obstruction and ischaemic parenchymal extinction lesions that accumulate over time.
Shock and liver transplantation
The liver is largely supplied by portal vein blood, supplemented by arterial ﬂow. In shock, the portal
vein ﬂow and oxygen saturation are both severely decreased so that this vessel supplies little oxygen to
the liver. Ischaemic injury is typically characterized by hepatocellular coagulative necrosis conﬁned to
zone 3, which represents the region farthest from the blood supply. Hepatocyte cytoplasm becomes
swollen, eosinophilic, and amorphous while nuclei undergo lysis. At the margins of regions with
coagulative necrosis, apoptotic hepatocytes are often seen, with cell shrinkage and nuclear fragmen-
tation. During periods of reperfusion sinusoids become inﬁltrated with macrophages and neutrophils.
When hypotension is associated with intrahepatic vascular obstruction, anoxia is more complete and
cell death extends to zones 1 and 2, often with contiguous multiacinar areas of infarction. Ischaemic
bile duct lesions can also occur, especially after transplantation where hilar arteries are disturbed but
also in patients with hypotension or catecholamine administration [1].
Oxygen deprivation leads to cell death through coagulative (lytic) necrosis and apoptosis. These two
modes of cell death were, in early years, distinguished by morphology. Apoptosis can be conﬁrmed
using markers of DNA degradation (e.g. nick-end labelling) or the appearance of cytokeratin fragments
produced by caspases [2,3]. Although often considered to be distinct mechanisms of cell death, necrosis
and apoptosis share the late processes subsequent to mitochondrial calcium inﬂux. Thus many cells
display hybrid forms of cell death acknowledged by the term ‘necrapoptosis’ [4,5].
Ischaemic death of hepatocytes occurs in two phases including early anoxia and subsequent
reperfusion injury. During the anoxic period anaerobic metabolism results in cellular acidosis. Low pH
is protective and features of cell death are most prominent after reperfusionwhen pH rises. At alkaline
pH, mitochondrial calcium ions increase, possibly by active transport during repolarization. High
mitochondrial calcium triggers generation of reactive oxygen species (ROS) that promote inner
membrane injury, mitochondrial permeability transition, and mitochondrial swelling. From this stage,
subsequent events appear to depend on the severity of membrane injury. If severe, oxidative phor-
phorylation is decoupled and ATP is severely depleted, leading to irreversible membrane failure and
rapid cell death by necrosis. If less severe, there is sufﬁcient ATP generation to allow the active pro-
cesses that include caspase activation, followed by DNA degradation, cell shrinkage, formation of
surface blebs, and other features of apoptosis [5]. These processes require time, often measured in
hours, so are found in cells that have escaped necrotic cell death.
These hepatocellular events do not occur in isolation. In the setting of hepatic reperfusion, sinu-
soidal endothelial cells (SEC) also undergo apoptosis and necrosis, leading to platelet and neutrophil
adhesion and release of many active substances that cause recruitment and activation of other cells,
including Kupffer cells and T-lymphocytes. Active substances include nitric oxide (NO), ROS, ICAM-1,
TNF-a, other cytokines, activated complement, lysosomal proteases, calpains, granulocyte colony
stimulating factor, and interferon-gamma. NO produced in SEC normally regulates and protects the
hepatic circulation but production is decreased when these cells are denuded. ROS play a key role in
Kupffer cell activation and the release of TNF-a by many cell types. TNF-a induces release of cytokines
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mulation and activation, exacerbating local hepatocyte injury [6–8].
In addition to the direct damage to the liver parenchyma, the effect of shock on other organ systems
can have secondary effects on the liver. For example, with bowel ischaemia, endotoxin and bacteria are
released into the portal circulation, triggering innate immunity pathways.
Opportunities for therapy
The mechanisms involved in ischaemia and reperfusion injury are relevant to the management of
patients with shock, partial liver resection, and liver transplantation. The main strategy is to minimize
warm ischaemic time [9]. Another strategy is ischaemic preconditioning, where intermittent clamping
of the portal vasculature is performed prior to the full surgical ischaemic stress [10–12]. Pharmaco-
logical preconditioning of the donor organ with methylprednisolone prior to harvesting or later has
resulted in lower post-operative transaminase levels [13,14].
Strategies targeting the cold ischaemia period are beginning to be reﬂected in modiﬁed perfusion
ﬂuids with improved energy sources (alpha-ketoglutarate), antioxidants (N-acetylcysteine, Curcumin),
cytokine inhibitors, MMP inhibitors (RXP409), vasodilators (nitroglycerin and prostaglandin E1,
endothelin antagonist TAK-044), NO precursors (L-arginine) and caspase inhibitors (IDN-6556) [2,6,15].
Curcumin shows promise as a cryoprotective agent that activates haem oxygenase-1 (HO-1). HO-1
catalyses breakdown of haem to biliverdin and bilirubin whose antioxidant properties reduce ROS
production. Pentoxifylline improves graft microcirculation by reducing TNF-a and inducing the anti-
inﬂammatory cytokines IL-6 and IL-10.
Strategies targeting the organ recipient prior to reperfusion include administration of N-ace-
tylcysteine and inhaled NO. N-acetylcysteine increases hepatic glutathione and decreases ROS pro-
duction, Kupffer cell activation, leukocyte recruitment, and platelet aggregation [6,8,11,16,17]. N-
acetylcysteine and inhaled NO both decrease post-operative aminotransferase levels [18,19].Liver in congestive heart failure (congestive hepatopathy)
Patients with congestive heart failure often develop ‘cardiac sclerosis’ characterized by mild to
moderate sinusoidal ﬁbrosis and zone 3 hepatocellular atrophy. The ﬁbrosis is patchy, occurring in
regions where hepatic veins have become obstructed [20]. The mechanism of ﬁbrogenesis likely in-
volves congestive hepatic vein damage, with or without thrombosis, followed by venous occlusion,
sinusoidal congestion, and hepatocellular necrosis [21]. Small bile duct lesions may also occur, likely a
result of ischaemia, that mimic various biliary diseases [22].Intrahepatic vascular obstruction
Intrahepatic vascular obstruction may occur with many systemic as well as intrahepatic diseases
[21]. The mechanisms may involve thrombosis, ligation, trauma, embolization, tumour inﬁltration,
congestive venous injury, or venous inﬂammation. Venous inﬂammation occurs in many conditions,
including acute and chronic hepatitis, pancreatitis, appendicitis, sarcoidosis, cholecystitis, abscess, and
Behcet’s disease. These lesions may result in infarcts of parenchyma or bile ducts. Portal vein throm-
bosis seldom causes infarcts because of compensatory arterial supply. Outﬂowobstruction by itself (e.g.
hepatic vein thrombosis) causes severe congestive necrosis, often exacerbated by secondary portal vein
thrombosis.
The mechanism of thrombosis is complex because concurrence of etiologic factors is usually
present. Typically, an underlying hypercoagulable state is revealed by incidental trauma or inﬂam-
mation to the vessel wall. Hypercoagulable states are found in association with a variety of myelo-
proliferative diseases and genetic or acquired factor abnormalities (e.g. oral contraceptives,
pregnancy, prothrombin G20210A, factor V Leiden, lupus anticoagulant, antiphospholipid antibodies,
ADAMTS13 deﬁciency, and protein C or S deﬁciency). Miscellaneous causes include metastatic
adenocarcinoma, idiopathic thrombocytopenic purpura, homocystinemia, and paroxysmal nocturnal
haemoglobinuria.
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eclampsia, and antiphospholipid syndrome with secondary ischaemic necrosis that is often prominent
in zone 1 [23,24]. When lesions are severe there may be large infarcts and hepatic rupture [25] (see
Innate immunity section).
Other causes of obstruction include malignant cellular inﬁltration as seen with metastatic carci-
noma, angiosarcoma, lymphoma, hairy cell leukaemia, and myeloma. Non-malignant inﬁltration oc-
curs with mastocytosis, hemophagocytic lymphohistiocytosis, Gaucher’s disease,
mucopolysaccaridosis, and sickle cell disease. Extracellular matrix may accumulate in amyloidosis and
light chain disease to cause liver dysfunction or portal hypertension.
Intrahepatic vascular obstruction in hepatitis
Hepatitis can be deﬁned as inﬂammation of the liver. While usually considered in the context of
infection with one of the hepatitis viruses, most of the systemic conditions discussed in this chapter
lead to a form of hepatitis. Secondarymicrovascular inﬂammation and obstruction occurs in all of these
forms of acute and chronic hepatitis. Very small obstructive lesions are well tolerated, as collateral ﬂow
prevents ischaemic injury. However, when hepatic vein obstructive lesions are larger, clusters of he-
patocytes die and leave behind small regions of sinusoidal collapse called parenchymal extinction
lesions. When numerous, these lesions become conﬂuent, remodelling over time to form arborizing
septa that we recognize as cirrhosis [21,23].
The microvascular lesions occur in sinusoids, terminal portal veins and terminal hepatic veins. In
hepatitis, these lesions are initially inﬂammatory in nature. Once the tissue pressure is chronically
elevated, oedema and haemorrhage in thewalls of small vessels, a process called congestive venopathy,
results in accumulation of ﬁbrous tissue in veins, the sinusoidal spaces of Disse, and in the septal
interstitium. These mechanisms are relevant to the progression of steatohepatitis, discussed below.
Toxic vascular injury
Oxaliplatin is a drug widely used for colon carcinoma with a high prevalence of toxic microvascular
injury (also known as sinusoidal obstruction syndrome or veno-occlusive disease). The drug causes
sinusoidal endothelial necrosis with secondary loss of hepatocytes, usually in microscopic foci but
occasionally up to one or more centimetres in diameter. Endothelial glutathione is depleted suggesting
that oxidative injury may be an important mechanism. Upregulation of metallopeptidase-9 causes
detachment of endothelial cells with exacerbation of local ischaemia [24]. Local thrombotic lesions
may occur. Lesions may be ameliorated by antioxidants [25,26], aspirin [27], and the anti-VEGF agent
bevacizumab [28].
Hyperperfusion
Hyperperfusion occurs downstream from arteriovenous shunts, leading to congestive injury and
ﬁbrosis. Artery-to-portal vein shunts cause arterialization and focal nodular hyperplasia [29]. Hyper-
perfusion also occurs when inappropriately small liver grafts are implanted. The resulting lesions
include congestive injury including endothelial necrosis, haemorrhage, and ﬁbrosis. In this setting,
there may be hepatic dysfunction and portal hypertension [30].
Innate immunity pathway
The innate immune system is an early defense system that responds to injury caused by toxins,
infectious agents, or trauma [31–33]. The system works by recognizing an injury or foreign substance
and then recruiting and activating inﬂammatory effector cells that can ameliorate the injury by
phagocytosis and microbial killing. Many cell types are involved in this system, including Kupffer cells,
natural killer cells, natural killer T cells, hepatic dendritic cells, SEC, hepatic stellate cells, and chol-
angiocytes. Activation of this system in the liver may be associated with aminotransferase elevations
and cholestasis. Histologically, there may be patchy necrosis of hepatocytes and cholangiocytes and
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aggregation, and thrombosis. Cholestasis may be prominent with canalicular dilatation, cytoplasmic
bile-staining, and necrosis of small bile ducts and ductules. These lesions are known as the ‘cholangitis
lenta’ lesion.
The reaction is initiated when molecules bearing pathogen-associated molecular patterns (PAMPs)
or damage-associated molecular patterns (DAMPs) interact with pattern recognition receptors (e.g.
Toll-like receptors (TLRs), helicase receptors, and Nod-like receptors). TLRs are expressed on Kupffer
cells, SEC, neutrophils, and hepatocytes. These interactions result in elaboration of pro-inﬂammatory
mediators that recruit the inﬂammatory cell inﬁltrate. Some agents also induce an antigen-speciﬁc
adaptive immune response.
Inﬂammatory inﬁltration involves the adhesion of neutrophils to the sinusoidal or venous endo-
thelium followed by emigration into the interstitium. This process proceeds in several pathways that
may involve selectins, integrins, chemokines, hyaluronic acid, leukotrienes, platelet activating factor,
and TNF-a. Once inﬂammatory cells are recruited, they amplify the reaction by the release other
mediators leading to phagocytosis, cell killing, and activation of hepatic stellate cells to synthesize
collagen.
Endotoxin is the most frequent activator of the innate immune system. Endotoxins are composed of
lipopolysaccharide (LPS) derived from the outer cell membrane of Gram-negative gut-derived bacteria.
When the intestinal barrier is compromised, LPS enters the portal circulation and binds to a Toll-like
receptor (e.g. TLR4) [32]. This binding initiates the activation of MAP-Kinase and NFkB leading to
transcription of TNF-a.
The role of TNF-a is multi-factorial and critical to the inﬂammatory response in the liver. In short, it
induces the production of other inﬂammatory cytokines (IL-1, IL-6, IL-10) and chemokines, causes
generation of reactive oxygen species (ROS), stimulates inducible nitric oxide synthase (iNOS) in SEC to
produce NO, and increases expression of integrins and other adhesion molecules necessary for
translocation of neutrophils [32,34]. All of these processes play a role in the recruitment of activated
neutrophils and subsequent hepatocyte and SEC damage. These processes also increase hepatocyte
production of coagulation factors, complement, and acute phase proteins [32].
Many cytokines enhance the inﬂammatory process, others inhibit it, and IL-6 does both. IL-6 binds
to its receptor subunit gp130 which activates Janus-Kinase-STAT3 complex causing STAT3 dimer for-
mation and translocation to the nucleus where it acts as a transcription factor. In hepatocytes, IL-6-
mediated activation of STAT3 enhances the inﬂammatory response and hepatocellular damage.
STAT3 induces transcription of acute phase proteins which have anti-apoptotic and antioxidant
properties. STAT3 activation in SEC and myeloid cells inhibits hepatocyte damage. IL-10 is an anti-
inﬂammatory cytokine that inhibits T cell proliferation and antigen presentation and attenuates in-
ﬂammatory gene expression in myeloid cells, also through activated STAT3.
Ethanol is a signiﬁcant modiﬁer of LPS-related liver damage. In non-infectious states, ingestion of
ethanol alone can cause increased LPS delivery to the liver by increasing gut microbial proliferation and
increasing gut permeability. Acetaldehyde, an ethanol metabolite, opens gut epithelial tight junctions
and disrupts cell adhesion molecules [35–38]. Ethanol also enhances inﬂammation by attenuating the
IL-6-induced STAT3 activation in monocytes and decreasing endotoxin-induced STAT3 activation in
SEC [36].Sepsis and cholestasis
Intrahepatic cholestasis is a well-recognized complication of sepsis [39,40]. The mechanisms are
diverse, involving altered function in hepatocyte and cholangiocytes. LPS-induced Kupffer cell release
of TNF-a and IL-1 causes disruption of the normal processing of bile salts related to internalization and
downregulation of canalicular transport proteins such as bile salt export pump (BSEP) and multidrug
resistant protein 2 (MRP2). There is also decreased expression of transport proteins on the basolateral
membrane that are responsible for bile acid uptake from the blood [39,40]. TNF-a, IL-1 and NO have
been shown to impair cAMP-dependent chloride and bicarbonate secretion in cholangiocytes [41,42].
Necrosis of ductular cells plays a mechanical role in cholestasis.
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Some bacterially produced exotoxins induce liver injury through alternate pathways that ultimately
converge onto the common pathway of Kupffer cell activation and the production of TNF-a, IL-1 and IL-
6. Superantigens such as Toxic Shock Syndrome Toxin-1 and Staphylococcus Exotoxin activate Kupffer
cells though theMHC Class II activation of T-helper cells. Pseudomonas aeruginosa Exotoxin A activates
Kupffer cells through T-helper cell-mediated immune response but without the use of MHC-II. Non-
bacterial endogenous toxins, such as those released in animal models of acute pancreatitis, also cause
liver injury through activation of Kupffer cells and release of TNF-a, IL-1 and IL-6, emphasizing the key
role of the liver in these systemic inﬂammatory conditions.
The virulence toxin pyocyanin of Pseudomonas aeruginosa causes liver injury by a different mech-
anism. Pyocyanin is a redox-active compound that reacts with oxygen to produce superoxide anion,
resulting in depletion of glutathione and ATP [43]. Injury to SEC has been noted in animal models [44].
HELLP syndrome and disseminated intravascular coagulation
HELLP is a syndrome with haemolytic anaemia, elevated liver tests (AST or bilirubin), and low
platelet count occurring during pregnancy, usually with preeclampsia. Histological changes include
sinusoidal injury with minute ﬁbrin deposits, haemorrhage, and focal hepatocellular necrosis.
The pathogenesis of HELLP is poorly understood. Most patients have evidence of placental stress
and increased pro-inﬂammatory cytokines in the blood [45]. Some patients have abnormalities in the
genes coding TLF4, glucocorticoid receptor, or FAS. Abnormalities of coagulation that might favour
thrombotic microangiopathy have been noted in some patients, such as antiphospholipid antibody,
factor V Leiden, decrease in the metalloproteinase ADAMT13, or abnormal VEGFA. Current opinion
suggests that inadequate immune tolerance allows injury to the developing trophoblast. This results in
release of foetal or placental materials (tissue factor, endoglin, VEGF-R1 (Flt1) and Fas ligand) as well as
blood clots and thrombin into the maternal circulation. These materials contribute to intravascular
ﬁbrin formation [46].
The liver injury may be explained by the microvascular obstruction and secondary ischaemia. This
mechanism is supported by the ﬁnding of sinusoidal ﬁbrin in the same location as the necrosis [47]. It
has also been suggested that Fas ligand may induce hepatocellular TNF-a and thereby trigger apoptosis
[48].
Hemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is a massive systemic activation of CD8þ T-lympho-
cytes andmacrophages resulting in inﬁltration of these cells in various organs including liver [49]. Liver
biopsies show sinusoidal inﬁltration with erythrophagocytosis, hepatocellular necrosis, and often bile
duct-injury [50,51]. HLH is triggered by infections (esp. EBV), autoimmune diseases (JRA, SLE, etc.) and
some malignancies and involves increased production of interferon-gamma, IL-1, IL-6, and TNF-a.
Many patients have genetic defects in the NK/T-cell cytotoxic pathway. In primary EBV infection, the
virus infects cytotoxic CD8þ cells leading to their impaired function. This dysfunction often acts in
concert with pre-existing mutations. HLH may also occur in systemic granulomatous diseases with
hepatic involvement (e.g. dengue, brucellosis, Q fever, various rickettsial diseases, tuberculosis,
leishmaniasis, and malaria) [49]. This may be a reﬂection of the importance of cytotoxic T cells in
defense against many of these diseases [52,53].
Opportunities for therapy
There are many potential therapeutic targets within the innate immunity cascade. There are several
agents that target TNF-a. These include pentoxifylline (TNF-a transcription factor inhibitor), Inﬂiximab
(monoclonal antibody against TNF-a) and Enterocept (TNF-a inhibitor). Unfortunately, the risk of
infection often outweighs any beneﬁt [32,54]. In the setting of sepsis, N-acetylcysteine administration
showed increased hepatic blood ﬂow and improved liver function [55]. Non-absorbable antibiotics (e.g.
rifaximin) have been proposed to decrease gut ﬂora in various clinical situations [54]. Therapeutic
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example, activated protein C inhibits the transcription of TNF-a, enhances expression of anti-apoptotic
genes, and decreases the production of cell adhesion molecules, all of which attenuate the inﬂam-
matory response in LPS-related liver injury [57].Adaptive immunity pathway
Immune-mediated liver injury is characterized by hepatocellular or cholangiocyte cell death with
inﬁltration by lymphocytes and plasma cells, often with progression to cirrhosis. These diseases are
classiﬁed according to the aetiology or mechanism. The most frequent forms are initiated by infection
with Hepatitis B virus or Hepatitis C virus. Virus negative cases usually have serum autoantibodies and
are classiﬁed as autoimmune hepatic diseases. The dominant types are autoimmune hepatitis, primary
biliary cirrhosis, and primary sclerosing cholangitis. The morphology is usually distinct in these dis-
eases. Autoimmune hepatitis tends to have more plasma cells than viral hepatitis. Chronic hepatitis B
frequently has hepatocellular inclusions of viral proteins. Primary biliary cirrhosis had dominant duct-
injury characterized by necrosis and granulomatous response. In addition to the dominant types, a
variety of other clinic-pathologic entities exist, including various combinations of overlap that are
difﬁcult to diagnose. Other immune-mediated hepatitides include IgG4 disease, sarcoidosis, post-
transplant allograft rejection [58], post-transplant de novo autoimmune hepatitis, and graft-versus-
host disease. Systemic autoimmune diseases, including SLE, RA, and PSS, and celiac disease may
have a dominant microvascular injury with arteritis or venulitis evolving to nodular regenerative
hyperplasia with non-cirrhotic portal hypertension [21]. Sarcoidosis also involves venous inﬂamma-
tion producing non-cirrhotic or cirrhotic disease [59].
The pathogenesis of autoimmune diseases is considered to include an initiating step that produces
disease in genetically abnormal hosts with a pre-existing abnormal immune system [60]. Genetic
susceptibility is conferred by particular HLA alleles or polymorphisms in genes for cytotoxic T-
lymphocyte antigen-4, tumour necrosis factor-alpha gene promoter, or Fas.
While the initiator is usually unknown, evidence in speciﬁc cases has implicated exogenous agents
known to cause liver injury, including hepatitis C virus, bacteria, and certain drugs, possibly through
molecular mimicry or by exposure of hepatic antigens in the course of the primary injury.
The mechanisms of injury are thought to begin when self-directed peptides are processed and
presented by antigen presenting cells in the liver (macrophages, dendritic cells, SEC, and others). The
subsequent response depends on the cytokines present. There are several positive feed-back loops
resulting in increased plasma cells producing autoantibodies and increased CD8þ effector T cells or
gamma-delta T cells. Natural killer cells are also activated.
The regulation of this complex sequence may be aberrant in autoimmune liver disease. Examples
are mutations in the autoimmune regulator-1 gene that prevents adequate removal or prevention of
auto-reactive Tcell clones. Regulatory Tcells appear to be decreased in function and number in patients
with autoimmune hepatitis, favouring unrestrained CD4 and CD8 effector cell proliferation. Other
aberrant pathways are under investigation.
Aberrant immunoregulatory mechanisms have been seen after exposure to drugs that selectively
suppress parts of the immune response. For example, anti-TNF monoclonal antibodies and interferon
have been reported to cause autoimmune hepatitis. Corticosteroids may cause an autoimmune
hepatitis-like disease, especially in patients with multiple sclerosis [61].Hormonal effects: insulin and nutrition
Obesity and type II diabetes mellitus are the major risk factors for non-alcoholic fatty liver disease
(NAFLD). NAFLD is subclassiﬁed histologically as simple steatosis or steatohepatitis (NASH). Simple
steatosis is characterized by the accumulation of large triglyceride droplets within hepatocytes. NASH
is deﬁned by steatosis accompanied by ballooning necrosis, often with Mallory-Denk bodies and
neutrophilic inﬂammation as well as ﬁbrosis or cirrhosis. NASH represents the most frequent cause of
cirrhosis in the western world.
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insulinemia and hypertriglyceridemia (Figs. 1–3). Insulin acts directly on hepatocytes to cause tri-
glyceride accumulation. This was ﬁrst shown in humans by the presence of subcapsular steatosis and
steatohepatitis in patients with insulin deﬁciency (type I diabetes) who were receiving insulin therapy
via peritoneal dialysis ﬂuid [62]. Several studies support a direct effect of insulin on the liver. Steatosis
occurs in liver tissue surrounding hepatic metastases of endocrine tumours secreting insulin (insuli-
noma) [63]. The distribution of hepatocellular steatosis is determined by proximity to the insulin
source. Focal fatty change occurs near the hilum of the liver when pancreatic veins supply insulin
directly to the region (Fig. 2) [64]. Insulin deﬁcient adult BB mice do not develop fatty liver when given
a choline deﬁcient diet [23,65]. It is likely that the steatohepatitis occurring in obese subjects after
jejuno-ileal bypass surgery is also related to high insulin levels in the presence of free fatty acid
mobilization during post-bypass weight loss [66].
The pathogenesis of NASH with progression to cirrhosis can be described with a four-step model:
(1) insulin-driven lipid accumulation, (2) intracellular lipotoxicity with ballooning necrosis, (3) bulk
lipid release with microvascular inﬂammation and obstruction, and (4) congestive necrosis with
septation [23].
Insulin favours hepatocyte lipid accumulation by several effects, including increased fatty acid
synthesis and esteriﬁcation, inhibition of lipid beta oxidation, and inhibition of VLDL secretion (Fig. 3).
The transition of steatosis to steatohepatitis may be caused by intracellular lipotoxicity. Triglyceride
(TG) accumulation is thought to be an indication of increased lipid trafﬁc but stored TG are themselves
relatively inert. However, free fatty acids (FFA), especially saturated forms, cause hepatocellular injury.
The mechanism is poorly understood. One pathway is that saturated lipids incorporated into endo-
plasmic reticulum membrane phospholipids displace unsaturated lipids leading to increased mem-
brane stiffness and altered function. The results include activation of the unfolded protein response,
activation of JNK signalling, increased endoplasmic reticulum Caþþ release, increased mitochondrial
permeability transition, and activation of cell death pathways [67]. Another pathway is through the
generation of ROS, depletion of mitochondrial glutathione, and secondary lipid peroxidation [68,69].
Lipid release into the interstitium causes an intense inﬂammatory reaction in any tissue, as seen in
traumatized adipose tissue and in ischaemic fatty livers after transplantation. In the liver, this pattern
of injury is called lipopeliosis [23,70]. In NASH, once rupture of fat-ﬁlled hepatocytes has occurred,
liberated fat causes inﬂammatory inﬁltration, microvascular obstruction, and ﬁbrosis, explaining thePancreatico-
duodenal vein
Pyloric vein
Superior mesenteric einv
Focal fatty change
Pancreas
Focal fatty sparing
Fig. 2. Hyperinsulinemia causes steatosis as demonstrated by these experiments of nature. An irregular system of veins (peribiliary
veins of Couinaud) drains blood from the pancreas or pyloric region directly to perihilar hepatic parenchyma. Blood from the
pancreas is high in insulin (red). When this blood reaches the liver parenchyma without dilution from the superior mesenteric vein,
focal fatty change results [64]. Blood from the pylorus is low in insulin (blue) leading to focal fatty sparing when there is background
steatosis [81].
Triglyceride Ketone bodies
Insulin
Lean
VLDL
FFA
Mitochondria
Obese
Triglyceride
Steatosis
Ketone bodies
Insulin
Insulin resistance
VLDL
Mitochondria
Peroxidation
Direct toxicity
FFA
Fig. 3. Effect of insulin on hepatocytes. The environment of hepatocytes differs in lean and obese individuals. The former have low
insulin and free fatty acid (FFA) levels in plasma. This load of FFA is easily cleared from hepatocytes as VLDL or ketone bodies. In
obesity, insulin resistance occurs, leading to high insulin and FFA levels in plasma. As insulin inhibits mitochondrial beta-oxidation of
lipids, the load of FFA cannot be adequately metabolized or excreted, leading to steatosis and lipid toxicity (modiﬁed from Ref. [62]).
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local hepatocellular injury into a progressive tissue-wide injury.
Modiﬁers of the four-step hypothesis
Each of the four steps is complex and many possible modiﬁers have been proposed.
Dietary composition
Although caloric intake is largely responsible for the development of obesity and hyperinsulinemia,
dietary composition is also important. Saturated and trans-unsaturated fats, cholesterol, and fructose
are of interest [69,71]. Choline deﬁciency, well documented to cause steatosis in rodent models, may
have a role in human fatty liver disease by altering the microbiome [72]. Quantity of visceral adipose
stores correlates with NAFLD better than total adiposity. This is likely because FFA released from this
store arrives directly in the liver via the portal vein.
The gut microbiome is altered by dietary composition. Such alterations may predispose to NASH,
possibly by altering satiety, increasing caloric absorption, increasing lipid synthesis, and increasing
endotoxemia and TLR-4 activation [73,74]. Generation of ethanol from gut ﬂora has been suggested to
contribute to NASH.
Alcohol and other toxins
Alcohol use augments steatohepatitis in patients with obesity [75,76]. Indeed the mechanisms of
steatohepatitis in NASH and alcoholic disease may be similar and synergistic. A number of drugs cause
steatohepatitis, including amiodarone, tamoxifen, perhexiline maleate, and synthetic oestrogens.
Genetic predisposition
A number of polymorphisms have been identiﬁed as possible modiﬁers of NAFLD. A mutation in the
PNPLA3 (adiponutrin) domain correlates with steatosis and ﬁbrosis in NAFLD, as well as with ﬁbrosis in
alcoholic and other forms of chronic liver disease [77,78]. This mutation is associated with abnor-
malities of triglyceride synthesis and hydrolysis. Lipid metabolism may also be altered by mutations in
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glyceride transfer protein [79]. Insulin sensitivity may be altered by polymorphisms in ectoenzyme
nucleotide pyrophosphate phosphodiesterase-1 and insulin receptor substrate-1 [80].Practice points
 Understanding the mechanisms of injury is critical for the design of therapeutic strategies.
 The mechanisms involved in ischaemia and reperfusion injury are relevant to the manage-
ment of patients with shock, partial liver resection, and liver transplantation. In trans-
plantation, themain strategy is tominimizewarm ischaemic time. Ischaemic preconditioning
may be useful. Improved perfusion ﬂuids may provide improved energy sources, antioxi-
dants, cytokine inhibitors, and vasodilators, and caspase inhibitors. N-acetylcysteine,
administered to the recipient may be beneﬁcial.
 The activation of the innate immune system can be suppressed with anti-TNF-a antibodies,
pentoxifylline, non-absorbable antibiotics, and blockade of the coagulation cascade with
activated protein C.
 Non-alcoholic steatohepatitis is caused by hyperinsulinism. This is best controlled with di-
etary restriction and avoidance of high-glycaemic foods.References
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